300529.SZ SHZ
Jafron Biomedical Co.,Ltd.
1W: +0.0%
1M: -3.2%
3M: -5.8%
YTD: -24.9%
1Y: -34.5%
3Y: -29.1%
5Y: -79.9%
¥15.27 ($2.28)
+0.34 (+2.28%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$5.4B
-2.9% ▼
5Y CAGR: +16.6%
Total Liabilities
$2.0B
-14.3% ▼
5Y CAGR: +44.6%
Shareholders Equity
$3.3B
+5.9% ▲
5Y CAGR: +9.2%
Cash & Investments
$2.3B
-17.5% ▼
5Y CAGR: +12.8%
Total Debt
$1.2B
-27.9% ▼
5Y CAGR: +82.0%
Net Debt
-$532M
+53.1% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $1.6B | $2.3B | $2.6B | $2.8B | $1.7B |
| Short-Term Investments | $0 | $150M | $0 | $0 | $593M |
| Cash & ST Investments | $1.6B | $2.5B | $2.6B | $2.8B | $2.3B |
| Net Receivables | $216M | $308M | $240M | $0 | $59M |
| Inventory | $121M | $197M | $349M | $385M | $338M |
| Other Current Assets | $75M | $12M | $36M | $105M | $20M |
| Total Current Assets | $2.0B | $3.1B | $3.3B | $3.3B | $2.8B |
| Property, Plant & Equip. | $906M | $1.3B | $1.7B | $1.8B | $1.9B |
| Goodwill & Intangibles | $134M | $145M | $138M | $113M | $105M |
| Long-Term Investments | $119M | -$39M | $69M | $116M | -$476M |
| Other Non-Current Assets | $58M | $349M | $207M | $202M | $1.0B |
| Total Non-Current Assets | $1.2B | $1.8B | $2.1B | $2.2B | $2.6B |
| Total Assets | $3.2B | $4.8B | $5.4B | $5.5B | $5.4B |
| — Liabilities — | |||||
| Accounts Payable | $50M | $61M | $129M | $136M | $119M |
| Short-Term Debt | $0 | $0 | $317M | $262M | $78M |
| Deferred Revenue | $27M | $320M | $42M | $0 | $0 |
| Other Current Liabilities | $31M | $6M | $295M | $63M | $213M |
| Total Current Liabilities | $331M | $386M | $717M | $829M | $767M |
| Long-Term Debt | $0 | $897M | $937M | $1.4B | $1.1B |
| Other Non-Current Liab. | -$12M | $125M | $155M | $0 | $6M |
| Total Non-Current Liabilities | $52M | $1.0B | $1.1B | $1.6B | $1.3B |
| Total Liabilities | $383M | $1.4B | $1.8B | $2.4B | $2.0B |
| — Equity — | |||||
| Common Stock | $799M | $805M | $808M | $808M | $799M |
| Retained Earnings | $1.4B | $1.9B | $2.1B | $2.0B | $2.5B |
| Accumulated OCI | $331M | $31M | -$5M | $551M | $120M |
| Total Stockholders Equity | $2.8B | $3.4B | $3.6B | $3.1B | $3.3B |
| Total Liabilities & Equity | $3.2B | $4.8B | $5.4B | $5.5B | $5.4B |
| — Key Metrics — | |||||
| Total Debt | $30M | $918M | $1.3B | $1.7B | $1.2B |
| Net Debt | -$1.5B | -$1.4B | -$1.3B | -$1.1B | -$532M |
| Total Investments | $119M | $111M | $69M | $116M | $117M |